Biotech firms Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio, which will develop gene-editing therapies. The new company raised $75m in a funding round led by Cormorant Asset Management and others, with the funds to be used to continue developing a lead therapy for liver disease. The company plans to build a broad pipeline of epigenetic editors that target hepatic and extrahepatic diseases.
Scam Sniffer Warns Fake Influencers Are Stealing Crypto Funds
ScamSniffer has issued a warning about crypto scammers using fake influencer accounts to lure victims into malicious Telegram groups. The scammers employ a malware known
